Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA


Long-term expression of coagulation factor IX (FIX) has been observed in murine and canine models following administration of recombinant adeno-associated viral (rAAV) vectors into either the portal vein or muscle. These studies were designed to evaluate factors that influence rAAV-mediated FIX expression. Stable and persistent human FIX (hFIX) expression (> 22 weeks) was observed from 4 vectors after injection into the portal circulation of immunodeficient mice. The level of expression was dependent on promoter with the highest expression, 10% of physiologic levels, observed with a vector containing the cytomegalovirus (CMV) enhancer/β-actin promoter complex (CAGG). The kinetics of expression after injection of vector particles into muscle, tail vein, or portal vein were similar with hFIX detectable at 2 weeks and reaching a plateau by 8 weeks. For a given dose, intraportal administration of rAAV CAGG-FIX resulted in a 1.5-fold or 4-fold higher level of hFIX compared to tail vein or intramuscular injections, respectively. Polymerase chain reaction analysis demonstrated predominant localization of the rAAV FIX genome in liver and spleen after tail vein injection with a higher proportion in liver after portal vein injection. Therapeutic levels of hFIX were detected in the majority of immunocompetent mice (21 of 22) following intravenous administration of rAAV vector without the development of anti-hFIX antibodies, but hFIX was not detected in 14 immunocompetent mice following intramuscular administration, irrespective of strain. Instead, neutralizing anti-hFIX antibodies were detected in all the mice. These observations may have important implications for hemophilia B gene therapy with rAAV vectors. (Blood. 2001;97:1258-1265)

© 2001 by The American Society of Hematology

Introduction

Hemophilia B is an X-linked bleeding disorder that results from a deficiency of blood coagulation factor IX (FIX). It affects 1 in 30,000 males and is characterized by spontaneous and extended bleeding episodes that can be life threatening. Current treatment for hemophilia B with plasma-derived or recombinant FIX, although effective at preventing and arresting hemorrhage, requires frequent intravenous administration. Prophylactic therapy aimed at maintaining FIX concentration at approximately 2% of physiologic levels is effective at reducing the incidence of life-threatening bleeds and the chronic manifestations of recurrent bleeding episodes but is prohibitively expensive and not widely available.

Considerable attention has recently focused on somatic gene therapy for hemophilia B, as it offers the potential for persistent therapeutic levels of circulating FIX. Although a number of gene transfer systems have been evaluated, recombinant adeno-associated viral (rAAV) vectors show significant promise for in vivo gene therapy for hemophilia B in that it is possible to achieve persistent therapeutic expression of FIX leading to the correction of the bleeding phenotype in FIX knockout mice following a single administration of rAAV vectors.4,5,9-11 These studies have subsequently been extended to the hemophilia B dog model in which several groups have demonstrated sustained expression of canine FIX (cFIX), leading to amelioration of the bleeding phenotype in some cases.4,7 Recent studies have documented the safety of intramuscular administration of rAAV to adult men with FIX deficiency and suggest that partially corrective levels of FIX can be achieved.9

Although these pioneering studies have clearly established the potential of rAAV-mediated gene therapy for hemophilia B, a number of issues remain unresolved. Various vectors and routes of administration have been used in different laboratories without systematic comparison. Specifically, the relative levels of FIX achieved by intramuscular injection versus systemic venous (tail vein) or hepatic venous (portal vein) injection have not been defined. The propensity of rAAV to induce a FIX-neutralizing antibody response following intramuscular injection but not after portal vein injections in immunocompetent animals and the implications of these observations with respect to the use of the intramuscular route for human gene therapy remain unresolved.4,9-11 Our studies were designed to address these gaps in our knowledge regarding rAAV-mediated FIX gene therapy.

Materials and methods

rAAV-hFIX vector construction and purification

The vectors used in these studies are shown diagrammatically in Figure 1. To construct rAAV vector pAV cytomegalovirus (CMV) enhancer/β-actin promoter complex (CAGG)-FIX, a cloning intermediate (pAV CAGG) was

From the Division of Experimental Hematology, Department of Hematology/Oncology, and Department of Surgery, St Jude Children’s Research Hospital, Memphis, TN.

Submitted June 5, 2000; accepted October 16, 2000.

Supported by grant P01 HL 53749 from NHLBI Program Project, by grant 94-00 from the ASSISI Foundation of Memphis, and by the American Lebanese Syrian Associated Charities (ALSAC). A.C.N. was supported by grant 049894/114 from the Wellcome Trust.

Reprints: Arthur W. Nienhuis, Experimental Hematology, St Jude Children’s Research Hospital, 332 N. Lauderdale, Memphis, TN 38105; e-mail: arthur.nienhuis@stjude.org.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

© 2001 by The American Society of Hematology
Figure 1. Structure of rAAV hFIX vector plasmids. (A) Recombinant AAV plasmid pAV CAGG-FIX consists of CMV-IE enhancer, β-actin promoter, a chicken β-actin/rabbit β globin composite intron (CAGG), 1.6-kb human FIX cDNA (hFIX) and a rabbit β globin polyadenylation signal (hatched box) flanked by the AAV ITRs. (B) pAV MSCV-FIX expression cassette consists of the 5' murine stem cell leukemia virus (MSCV) long terminal repeat (LTR) together with its splice signals (IVS), hFIX cDNA and a human ß globin polyadenylation signal (hatched box) flanked by the AAV ITRs. (C) In pAV CMV-FIX-YFP, the CMV IE enhancer/promoter (CMVe/p) is followed by a synthetic intron that promotes efficient splicing (syn IVS). The promoter controls the expression of a bicistronic transcript encoding the hFIX gene and the enhanced yellow fluorescence protein (EYFP) gene separated by the encephalomyocarditis virus internal ribosomal entry site (ires). Transcription in this cassette is terminated by the bovine growth hormone polyadenylation signal (bGH pA, hatched box). (D) pAV HBPC FIX is identical to rAAV CMV-FIX except that the bicistronic transcript is under the control of the hepatitis B enhancer I and II region (ENI and ENII) and pre-core promoter derived from the hepatitis B viral (subtype ADW) genome. The EcoRI restriction enzyme sites used to generate the hFIX fragment is shown. The arrow beneath the construct indicates the size of the individual rAAV expression cassettes.

first created by the ligation of a 2.23-k base pair (bp) HincII-HindIII (blunt) fragment from plasmid pCAGGS,12 encompassing the CMV-IE enhancer, β-actin promoter, a chicken β-actin/rabbit β globin composite intron, and a rabbit β globin polyadenylation signal (CAGG) into the SnaBI-StuI sites of pSUB201.13 This created a plasmid in which the CAGG expression cassette was flanked by the AAV inverted terminal repeats. The hFIX complementary DNA (cDNA) was excised from pBS-FIX14 with BamHI and cloned into the BglII site of pAV CAGG to generate pAV CAGG-FIX (Figure 1A). The pAV MSCV-FIX expression cassette consists of the 5' murine stem cell leukemia virus (MSCV) long terminal repeat derived from plasmid MGirL22Y,15 the 1.6-kb BamHI hFIX cDNA, and human β globin polyadenylation signal flanked by pSUB201 AAV inverted terminal repeats. Plasmid pAV CMV-FIX-YFP was made by cloning a blunt-ended BamHI 1.6-kb hFIX cDNA into the blunt Nsil site of pRES-YFP (Clontech, Palo Alto, CA). The bicistronic expression cassette was digested by digesting with NruI and BsrI107I and cloned into the SnaBI/BsrI1107I site of pSUB201. pAV HBPC FIX was constructed by replacing the CMV-IE enhancer promoter complex of pAV CMV-FIX with a 734-bp fragment consisting of the hepatitis B enhancer I (ENI; nt 1068 to 1231) and II region (ENII; nt 1631 to 1741) and pre-core promoter (nt 1814 to 1900) derived from the hepatitis B viral genome (subtype ADW, GenBank accession no. V00866) and the synthetic intron from pRES-YFP.

AAV vectors were made by the transient transfection method described before.16 In brief, subconfluent 293T cells either in cell factories (Nunc, Roskilde, Denmark) or plated on 15-cm plates were cotransfected with the hFIX vector plasmid, a helper plasmid encoding the adenoviral helper genes 80-XXI necessary for AAV production and a packaging plasmid (XXII), or split packing plasmids (pRep-Ad and pCMV-Cap) using the calcium phosphate method. Cells were harvested between 50 to 60 hours after transfection and lysed by incubation with 0.5% deoxycholate (Fisher Scientific, Pittsburgh, PA) in the presence of 50 U/mL Benzonase (Sigma, St Louis, MO), for 30 minutes at 37°C. Following centrifugation at 6000g, the rAAV particles were isolated by affinity column chromatography.18 Standard slot-blot analysis was used to determine the vector particle titer. Contamination with wild-type (wt) AAV was determined by a polymerase chain reaction (PCR) assay described before.16 Aliquots of rAAV were periodically subjected to polyacrylamide gel electrophoresis to determine the degree of contamination with cellular proteins. The vector stocks were consistently free of contamination with wt AAV cellular and adenoviral proteins.

Cell culture and in vitro transduction with rAAV-hFIX vectors

Human embryonic kidney (293T) and human hepatoma (HepG2) cells were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U penicillin per mL, and 0.1 mg streptomycin per mL (D10), at 37°C in a humidified atmosphere containing 5% CO2. The liver-derived HepG2 cells express a number of clotting viral proteins.

To establish that the rAAV-hFIX vectors can directly express hFIX, 1×107 HepG2- or C57Bl/6-derived primary myoblasts were isolated from neonatal C57Bl/6 mice as described previously20 and grown in a 1:1 mixture of F-10 and DMEM (GIBCO BRL, Gaithersburg, MD) supplemented with 20% FCS and 2.5 ng/mL basic fibroblast growth factor (Promega, Madison, WI) on collagen-coated plates. To establish that the rAAV-hFIX vectors can directly express hFIX, 1×107 HepG2- or C57Bl/6-derived primary myoblasts were transduced overnight in serum free media with 1×10^10 vector genomes. Twenty-four hours conditioned media were collected on day 4 after transduction and assayed for hFIX, using the Asserachrom IX:ag enzyme-linked immunosorbent assay (ELISA) kit (American Bioproducts, Parsippany, NJ). Levels of hFIX as low as 20 ng/mL could be detected with this assay.

In vivo transduction with rAAV FIX vectors

C57Bl/6 immunoconpetent mice and mice with severe combined immunodeficiency disease (SCID) were obtained from Jackson Laboratory (Bar Harbor, ME). The C57Bl/6 strain of mice was chosen because previous studies indicated that these animals do not produce a humoral response to hFIX.21-23 C.B-17 SCID-immunodeficient and BalB/C- and Fv129-immunocompetent mice were obtained from Charles River Laboratory (Wilmington, MA). All animals were treated according to the standards set in the care and use of laboratory animals by the National Institutes of Health. For intramuscular administration, 10-week-old male mice were anesthetized with methoxyflurane, and a 1-cm longitudinal incision was made in the lower limbs to expose the quadriceps and tibialis anterior muscle. rAAV FIX vector genomes (5 × 10^{10} to 1×10^{11}) in a total volume of 150 µL suspended in phosphate-buffered saline was injected equally into...
the 2 muscle groups at 5 to 6 sites (∼ 30 μL/site). Incisions were closed with 5-0 chromic gut sutures. The same dose of rAAV CAGG-FIX was injected into the tail veins of 10-week-old male mice as a single bolus injection. Mice undergoing intraperitoneal administration of rAAV vector were anesthetized with methoxyflurane. The portal vein was exposed following a right subcostal incision and displacement of intestine. The virus (between $5 \times 10^9$ and $1 \times 10^{11}$ genomes) in a maximum volume of 400 μL was injected slowly over 2 to 3 minutes into the portal vein, using a 30-gauge needle. A small piece of Gelfoam (Amersham PharmaCom, Arlington Heights, IL) was placed at the injection site to aid hemostasis before withdrawing the needle. The abdomen was closed layer to layer with 5-0 chromic gut sutures. Blood samples were collected at 14-day intervals from the retro-orbital plexus in 1/10 volume 3.2% citrate, and the hFIX concentration in murine plasma was determined by using the Asserachrom IX:ag ELISA kit (American Bioproducts). The probability of statistical concentration in murine plasma was determined by using the one-step activated partial thromboplastin time. One Bethesda unit was defined as the reciprocal of the dilution of test plasma at which 50% of FIX activity is inhibited. The sensitivity of the assay was 1 Bethesda inhibitor unit per milliliter.

**Detection of anti-AAV antibodies**

Plasma samples taken at 2 weekly time points after rAAV administration into immunocompetent mice were mixed (1:100 and 1:500, 1:1000 dilutions) with 1 × $10^9$ particles of a rAAV vector in which green fluorescent protein was under the control of the CAG promoter (rAAV CAGG-GFP) and incubated for 60 minutes at 37°C. Control reactions included plasma from transduced immunodeficient mice of the same strain. The reactions were subsequently used to transduce 1 × $10^5$ 293T cells/well in 12-well plates. Transduction efficiency was determined by assessing green fluorescent protein expression at 48 hours after exposure to the virus/antibody mix, using fluorescence-activated cell sorter analysis.

**Results**

**Comparison of rAAV-hFIX vectors**

Four different AAV vectors were constructed, each of which contained the hFIX cDNA under the transcriptional control of either constitutive (MSCV, CMV, CAGG) or liver-specific (hepatitis B enhancer/core promoter) regulatory elements (Figure 1). Splicing sequences were included between the promoter and hFIX cDNA in all the vectors, as these are critical for high-level FIX expression.30,31 The CMV and the CAGG promoter elements have been previously shown to have strong activity in muscle.11,28 The hepatitis B enhancer/core promoter complex was specifically chosen, as it has strong hepatocyte-specific activity.29,30 The activity of these rAAV vectors was assessed in vitro by

![Figure 2. In vitro evaluation of rAAV-hFIX constructs.](image-url)
transducing 1 × 10^11 HepG2- or C57Bl/6-derived primary myoblasts with 1 × 10^10 vector genomes. Twenty-four hours conditioned media were collected on day 4 after transduction and assayed for hFIX (Figure 2). hFIX was undetectable in conditioned media from untransduced cells. The highest levels of hFIX were achieved by transduction of HepG2 and myoblast cells with rAAV CAGG-FIX (21 ± 2 pg FIX/cell/24 hours in HepG2 cells and 9 ± 1 pg FIX/cell/24 hours in myoblasts). The CMV promoter had moderate activity (5 ± 0.2 pg FIX/cell/24 hours in HepG2 cells and 3 ± 0.3 pg FIX/cell/24 hours in myoblasts), whereas the MSCV promoter was relatively weak in both cell types (1 ± 0.3 pg FIX/cell/24 hours in HepG2 cells and 1.5 ± 0.2 pg FIX/cell/24 hours in myoblasts). Expression of hFIX was undetectable in conditioned media derived from myoblasts transduced with rAAV HBV-FIX, whereas moderate expression (6 ± 0.5 pg FIX/cell/24 hours respectively) was observed in conditioned media derived from HepG2 cells transduced with this vector.

To compare the activity of rAAV-hFIX vectors in vivo, 1 × 10^11 rAAV genomes were administered into the portal vein or tail vein of 7- to 10-week-old male C57Bl/6 SCID mice. Figure 3 shows the level of hFIX in the plasma of recipient mice for 30 weeks following gene transfer. The profile of expression for each vector was essentially the same, and the total amount of hFIX expressed was consistent within each group but varied substantially among the different vectors. FIX levels approaching 10% of physiologic levels were detected (506 ± 61 ng/mL) at 12 weeks and thereafter following the administration of rAAV CAGG-FIX (Figure 3A), whereas expression from the other vectors was substantially lower (20-54 ng/mL) (Figure 3B). The difference in the level of hFIX observed with rAAV CAGG-FIX compared to the other vectors was highly significant at all time points beyond 4 weeks (P < .001, using one-way ANOVA). This difference in the level of expression was not related to vector copy number as shown by Southern blot analysis of genomic liver DNA from selected animals (Figure 3C). The hFIX proviral DNA was detected in livers from each animal, ranging from approximately 0.15 to 0.3 proviral copies per diploid genome. Undigested DNA produced a smear without bands, whereas DNA restricted with XbaI that cuts once within the FIX cDNA vectors yielded discrete bands whose apparent molecular weights were equivalent to that of the provirus (data not shown). These data are consistent with previous reports that indicate that AAV exists as high molecular weight head-to-tail concatamers following transduction of murine hepatocytes.31

Influence of route of administration on rAAV-mediated hFIX plasma levels and distribution and expression of the rAAV genome

rAAV CAGG-FIX or rAAV CMV-FIX genomes (5 × 10^10) were injected intramuscularly (quadriceps and the tibialis anterior) or intravenously via the tail or portal veins of 2 different strains of immunodeficient mice (C57Bl/6 SCID or C.B-17 SCID) using the same batch of vector. The kinetics of hFIX expression for all 3 routes of administration in the C57Bl/6 SCID mice was similar (Figure 4) with hFIX detectable at 2 weeks and reaching steady state levels by 8 weeks. These levels were maintained for the duration of the study (30 weeks). Intraportal administration of rAAV CAGG-FIX resulted in a 4-fold higher level of hFIX (peak = 436 ± 25 ng/mL) compared to intramuscular injections (peak = 143 ± 66 ng/mL). This difference was highly significant (P < .01, using one-way ANOVA). hFIX expression following administration of rAAV CAGG-FIX via the tail vein peaked at 303 ± 77 ng/mL with steady-state levels approaching 80% of that observed in the cohort of mice receiving rAAV via the portal vein.
A similar pattern of expression was observed in C.B-17 SCID mice. Additionally, to determine if the difference in hFIX expression following different routes of administration was promoter specific, 1 x 10^10 genomes of rAAV CMV-FIX was injected into the portal vein or muscle of 10-week-old C.B-17 SCID mice. The level of hFIX following portal vein injection was 2.4-fold higher than that observed following intramuscular injection (44 ± 6 ng/mL and 18 ± 4 ng/mL, respectively; P < .05 using paired t test).

Vector DNA was detectable in all tissue samples examined at 22 weeks following tail vein administration of 5 x 10^10 genomes of rAAV CAGG-FIX with the majority detected in the liver and spleen (Figure 5A). Intraportal administration of the same number of rAAV CAGG-FIX particles resulted in the presence of the transgene in the liver with no evidence of spillover to the other organs, using a semiquantitative PCR assay capable of detecting 6 x 10^-4 copies per diploid genome. Significantly more spillover outside of the liver was observed following intramuscular injection (44 ± 15 ng/mL and 18 ± 4 ng/mL, respectively; P < .05 using paired t test).

Influence of route of administration on immunogenicity of hFIX and rAAV

rAAV CAGG-FIX was administered to C57Bl/6, Balb/C, and Fv129 strains of immunocompetent mice by the 3 routes of administration outlined above. Although a number of different batches of vector preparations were used, adequate precautions were taken to ensure that an equal number of animals in each of the cohort were transduced with the same batch of vector. Therapeutic levels of hFIX were detected (Figure 6) in 21 of 22 immunocompetent animals following either portal or tail vein administration of rAAV vector particles. The kinetics of hFIX expression in the C57Bl/6 mice was comparable to that observed in its immunodeficient counterpart, although the hFIX levels were lower (1 x 10^11 rAAV CAGG-FIX particles = 350 ± 31 ng/mL, 5 x 10^10 particles = 290 ± 73 ng/mL). As with the immunodeficient animals, the hFIX levels observed following tail vein administration were 77% of those following intraportal infusion. Balb/C and Fv129 strains of mice had comparatively lower levels of hFIX (19% and 62% levels in C57Bl/6 mice, respectively) that may be a reflection of the strain-specific variations in transgene expression reported by others. hFIX-specific antibodies were not detected by ELISA, Bethesda, or Western blot analysis in any of these animals.
Our studies were designed to evaluate parameters that influence the levels of FIX achieved after rAAV-mediated gene transfer. With the use of immunodeficient mouse strains, we identified the rAAV CAAG-FIX vector that has a constitutive CMV enhancer-β-actin promoter combination as giving the highest levels among the 4 vectors tested regardless of whether the vector was administered by the intramuscular route or via the systemic (tail vein) or hepatic (portal) venous circulation. The level of FIX achieved by the intraportal route (436 ± 25 ng/mL) was approximately 4-fold that observed with an equivalent number of vector particles injected intramuscularly. Surprisingly, tail vein injection yielded levels nearly equivalent (60%-80%) to those achieved with intraportal injection. In immunocompetent mice, intramuscular injection consistently resulted in the appearance of high levels of neutralizing antibodies against hFIX in 3 separate mouse strains, whereas delivery of the vector particles into the systemic or portal venous circulation did not invoke an immune response against the human protein.

The vector with liver-specific promoter performed less well in the context of the rAAV vector design then would have been predicted from its activity in hepatocytes using adenoviral vectors. Conversely, the CMV enhancer-β-actin promoter combination performed better when expressing FIX in the liver than prior studies would have suggested. The levels achieved were approximately 8% to 10% of the normal hFIX levels, sufficient to convert a severe hemophilic to a mild phenotype. These results underscore the continued unpredictable and empirical nature of vector design. Given the limitations in vector production and the problems inherent in scale up to provide sufficient vector particles to give a comparable vector dose to an adult human man, further improvement in vector design is desirable. In that context, the vector designated AAV-LSP-cFIX that contains a fragment from the thyroid hormone-binding globulin promoter and 2 copies of α1-microglobulin/bikunin enhancer sequences gave substantial higher levels of FIX in mice when injected via the portal vein than we have observed with a comparable dose of the rAAV CAAG-FIX vector given by the same route. However, when the cFIX cDNA in AAV-LSP-cFIX was replaced with its human counterpart, the FIX expression in HepG2 cells and C57Bl/6 SCID mice was below that observed with rAAV CAGG-FIX (unpublished observations).

Our studies provide the first direct comparison of FIX levels achieved via the hepatic versus systemic venous circulation with the same vector preparation given at the same total dose. The fact that the systemic venous route gives 60% to 80% of the levels achieved by intraportal injection undoubtedly reflects the known propensity of rAAV to collect in liver cells. An important practical implication of our results is that selective delivery via the hepatic artery through a percutaneous catheter, a technically less complex and risky procedure than portal vein injections in humans, may be the preferred route for rAAV-FIX administration to patients with hemophilia.

Our results suggest dose-dependent “spillover” of vector particles injected into the portal circulation. At a dose of 5 × 10¹⁰ vector particles, PCR analysis detected the rAAV genome predominantly in liver, whereas, at a dose of 1 × 10¹⁰ particles, a larger proportion of the vector genome was found in the spleen and other organs (Figure 4). Similar dose-dependent spillover has been observed when vector particles were given via the intramuscular route (ORDA web site, http://www.nih.gov/od/oba/3-99RAC.htm). Restricting the distribution of rAAV after hepatic artery injection to the liver seems desirable and may require that the dose of vector particles is kept within certain defined limits. This consideration further underscores the need to use a vector configuration that maximizes liver-specific expression.

Discussion

Our studies were designed to evaluate parameters that influence the levels of FIX achieved after rAAV-mediated gene transfer. With the
We used 2 different promoters to demonstrate that the liver is a more potent site for rAAV-mediated FIX production than muscle irrespective of mouse strain. This may reflect the fact that the liver is the natural site of FIX synthesis and has the necessary machinery for posttranslational modification of the mature protein. Although processing of FIX in myotubes has been documented, the relative efficiency of the gamma-carboxylation in muscle versus liver is unknown. More important, however, is the issue of inhibitory antibodies to transgene products. An earlier study reported neutralizing antibodies directed against hFIX following intramuscular injection of rAAV-hFIX vector particles in C57Bl/6 mice. Neutralizing antibodies against human α-antitrypsin have also been documented following intramuscular administration of rAAV vector. It was unclear, however, if this immune response was mouse strain specific or related to contamination of the vector preparation with adenovirus particles or cellular proteins. These questions have now been resolved in that we have identified neutralizing antibody formation in 3 mouse strains following intramuscular injection of rAAV preparations that were entirely free of adenoviral particles or protein contamination. These same vector preparations failed to invoke antibodies against hFIX when given via the venous circulation to the same strains of mice. There can be little doubt that the intramuscular route provides a different immune stimulus to the same protein in mice than does delivery of vector particles predominantly to the liver. The precise mechanism for this difference remains unclear, but it is possible that ectopic expression of proteins, such as clotting factor, in a site like the muscle could generate a novel immune response perhaps due to the formation of neoantigens as a result of improper processing of the transgene protein. In addition, hFIX antigen presentation following gene transfer into the muscle may be mediated through a different pathway.

Do these findings have implications with regard to human gene therapy applications? Three patients with hemophilia have now been given rAAV-hFIX particles via the intramuscular route without evidence of formation of neutralizing antibodies against FIX. However, a relatively low dose of rAAV vector particles was administered. Furthermore, each of the patients had a missense mutation in their FIX gene so that tolerance to FIX had undoubtedly been induced during normal development. A prior study in hemophilic dogs with a missense mutation in their FIX gene is also of some interest. In 2 of 5 animals given rAAV-cFIX, antibodies against cFIX were detected by Western blot analysis, with transient reduction in antigen levels. Further studies in this dog model indicate that the tendency to form neutralizing antibodies toward the transgene product following intramuscular administration is partially determined by the vector dose. All together, the data suggest that tolerance can be broken at least transiently in such animals.

Liver-targeted delivery through the hepatic artery seems the preferred route for administration of rAAV-FIX particles, both because of the potentially higher levels of FIX achieved and the absence of an immune response. Available evidence indicates that rAAV forms head-to-tail concatamers, perhaps via a rate-limiting dimer intermediate, and integrates into liver cell chromosomes. Thus, stable production of FIX observed in animal studies is likely to persist. Antibodies to AAV, previously observed by other investigators, were also documented in our studies presumably precluding readministration of rAAV of the same serotype. If necessary, rAAV of different serotypes could be readministered to augment FIX production over time.

Overall, rAAV seemed to hold significant promise for the treatment of hFIX deficiency.

Acknowledgments

We wish to thank Jean Johnson for her outstanding assistance in preparation of the manuscript and Professor George Brownlee for his gift of pBS-FIX.

References

17. Kay MA, Landen CN, Rothenberg SP, et al. In...


Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA